Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Available at: This article provides educational information about Retatrutide and cardiovascular health based on clinical trial data and published research
It was developed by Eli Lilly and received FDA approval under the brand names Mounjaro (for type 2 diabetes management) and Zepbound (for chronic weight management)
Source: Polaris Market Research Analysis Segmental Insights By Type of GLP-1 Agonist Drugs Analysis The segmentation, based on type of GLP-1 agonist drugs, includes long-acting GLP-1 agonist and short-acting GLP-1 agonist
Individuals should contact their GP or a relevant specialist before considering retatrutide if they have any of the following: A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2): Rodent studies with GLP-1 receptor agonists have identified thyroid C-cell changes
US$ 22.30
US$ 21.46
US$ 27.04
US$ 23.15
US$ 24.59
US$ 28.77
US$ 24.55
US$ 29.79
US$ 25.00
US$ 20.12
